Transient elastography-based risk estimation of hepatitis B virus-related occurrence of hepatocellular carcinoma: Development and validation of a predictive model

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 1463-1469

  Kim, Do Young ^a,b   Song, Ki Jun ^a,b   Kim, Seung Up ^a,b   Yoo, Eun Jin ^a   Park, Jun Yong ^a,b   Ahn, Sang Hoon ^a,b   Han, Kwang Hyub ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Liver Cirrhosis Clinical Research Centre   (South Korea)

Author keywords

Hepatitis B; Hepatocellular carcinoma; Prediction; Transient elastography

Indexed keywords

VIRUS DNA;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BOOTSTRAPPING; CANCER RISK; DIGESTIVE TRACT PARAMETERS; ELASTOGRAPHY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER STIFFNESS; MAJOR CLINICAL STUDY; MALE; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; TRANSIENT ELASTOGRAPHY; VALIDITY;

EID: 84886072846     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S51986     Document Type: Article

References (32)

1. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet. 1981;2:1129-1133.
2. Trichopoulos D, Bamia C, Lagiou P, et al. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. J Natl Cancer Inst. 2011;103:1686-1695.
3. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557-2576.
4. Bellentani S, Saccoccio G, Costa G, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut. 1997;41:845-850.
5. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579-591.
6. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-2917.
7. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337: 1733-1745.
8. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347:168-174.
9. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65-73.
10. Yang HI, Yuen MF, Chan HL, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol. 2011;12:568-574.
11. Chan HL, Hui AY, Wong ML, et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut. 2004;53:1494-1498.
12. Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology. 2003;124:327-334.
13. Yuen MF, Tanaka Y, Shinkai N, et al. Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. Gut. 2008;57:98-102.
14. Yuen MF, Tanaka Y, Fong DY, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol. 2009;50:80-88.
15. Park BK, Park YN, Ahn SH, et al. Long-term outcome of chronic hepatitis B based on histological grade and stage. J Gastroenterol Hepatol. 2007;22:383-388.
16. Jung KS, Kim SU, Ahn SH, et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology. 2011;53:885-894.
17. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med. 2001;344: 495-500.
18. Rousselet MC, Michalak S, Dupre F, et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology. 2005;41: 257-264.
19. Kim SU, Seo YS, Cheong JY, et al. Factors that affect the diagnostic accuracy of liver fibrosis measurement by Fibroscan in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2010;32:498-505.
20. Wong GL, Wong VW, Choi PC, Chan AW, Chan HL. Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. Aliment Pharmacol Ther. 2010;31:1095-1103.
21. Kim SU, Kim JK, Park YN, Han KH. Discordance between liver biopsy and Fibroscan(R) in assessing liver fibrosis in chronic hepatitis b: risk factors and influence of necroinflammation. PLoS One. 2012;7:e32233.
22. Jang HW, Kim SU, Park JY, et al. How many valid measurements are necessary to assess liver fibrosis using FibroScan(R) in patients with chronic viral hepatitis? An analysis of subjects with at least 10 valid measurements. Yonsei Med J. 2012;53:337-345.
23. Kim do Y, Kim SU, Ahn SH, et al. Usefulness of FibroScan for detection of early compensated liver cirrhosis in chronic hepatitis B. Dig Dis Sci. 2009;54:1758-1763.
24. Kim SU, Han KH, Nam CM, et al. Natural history of hepatitis B virus-related cirrhotic patients hospitalized to control ascites. J Gastroenterol Hepatol. 2008;23:1722-1727.
25. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236.
26. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol. 2006;101: 1797-1803.
27. Han KH, Ahn SH. How to predict HCC development in patients with chronic B viral liver disease? Intervirology. 2005;48:23-28.
28. Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ. 2004;328:983.
29. Hann HW, Fu X, Myers RE, et al. Predictive value of alpha-fetoprotein in the long-term risk of developing hepatocellular carcinoma in patients with hepatitis B virus infection-results from a clinic-based longitudinal cohort. Eur J Cancer. 2012;19:19.
30. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227-242.
31. Lok AS, McMahon BJ: Chronic hepatitis B: update 2009. Hepatology. 2009;50:661-662.
32. Leung N. Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues. Hepatol Int. 2008;2:163-178.